For information, the company have advised that they are no longer intending to provide an evidence submission for this appraisal at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6154 |
Project Team
| Project lead | Emily Richards |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 November 2024 | Suspended. For information, the company have advised that they are no longer intending to provide an evidence submission for this appraisal at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 15 May 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised. These timings will be available later in the year, and are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 26 February 2024 - 25 March 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 22 November 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-April 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 23 October 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid- January 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 05 September 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late-November 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-February 2024. |
| 15 February 2023 | Please note that belzutifan will not be included in the renal cell carcinoma pathways evaluation at this time. NICE and the company are continuing to liaise about scheduling for this topic and further participation in the pathway evaluations. |
| 21 November 2022 | Please note that the evaluation of belzutifan for previously treated advanced renal cell carcinoma will now be conducted via ID6186 considering multiple treatments for renal cell carcinoma. |
| 13 October 2022 | In progress. DHSC referral received |
| 11 July 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual